:: 가톨릭대학교 백혈병 연구소 ::
Num Title Journal name Journal date
16
Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Anticancer Drugs 2017 Jul;28(6):660-668. doi: 10.1097/CAD.0000000000000506.
15
Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Haematologica 2017 Nov;102(11):e456-e459. doi: 10.3324/haematol.2017.168070.
14
Induction of Indoleamine 2,3-dioxygenase by Pre-treatment with Poly(I:C) May Enhance the Efficacy of MSC Treatment in DSS-induced Colitis.
Immune Network 2016 Dec;16(6):358-365. doi: 10.4110/in.2016.16.6.358.
13
Attenuate Cutaneous Sclerodermatous Graft-Versus-Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration in a Mouse Model.
The Journal of Investigative Dermatology 2017 Sep;137(9):1895-1904. doi: 10.1016/j.jid.2017.02.986.
12
CD1d is a novel cell-surface marker for human monocytic myeloid-derived suppressor cells with T cell suppression activity in peripheral blood after allogeneic hematopoietic stem cell transplantation.
Biochemical and Biophysical Research Communications 2017 Nov 3. pii: S0006-291X(17)32187-3. doi: 10.1016/j.bbrc.2017.11.010.
11
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
THE KOREAN JOURNAL OF INTERNAL MEDICINE 31(5):809~819
10
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
BLOOD RESEARCH(구 대한혈액학회지/2013년 이후 게재) 51(3):193~199
9
MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease
MUCOSAL IMMUNOLOGY 9(3):730~743
8
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
ANNALS OF HEMATOLOGY 95(6):911~919
7
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
CANCER IMMUNOLOGY IMMUNOTHERAPY 65(8):983~994
    이전페이지 1 2 다음페이지
비밀번호 입력
비밀번호
확인
비밀번호 입력
비밀번호
확인